Engineered immune cells show promise against hard-to-treat leukemia

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 15-65 years of age at the time of signing informed consent * Diagnosed as de novo Philadelphia chromosome-positive CD19+ B-ALL * Karnofsky performance status ≥ 60 or Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Unable to find a suitable donor or for other reasons to undergo allogeneic hematopoietic stem cell transplantation during the study * Ability and willingness to adhere to the study visit schedule and all protocol requirements * Voluntarily sign informed consent forms Exclusion Criteria: * Unable to tolerate any kind of TKIs (including the first- and second-generation tyrosine kinase inhibitors) for a long period. * Subjects who have positive mutation(s) of the ABL kinase domain and require the third-generation tyrosine kinase inhibitors for long-term therapies. * Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 × upper limit of normal (ULN) and direct bilirubin \> 1.5 × ULN * Inadequate renal function defined by serum creatinine \> 1.6 mg/dL * International ratio (INR) or partial thromboplastin time (PTT) \> 1.5 x ULN * Left ventricular ejection fraction \< 50% * Ongoing treatment with chronic immunosuppressants * Significant comorbid conditions or diseases which, in the judgment of the investigator, would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions * Known human immunodeficiency virus (HIV) positivity * Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control * Subjects with second malignancies in addition to ALL * Pregnant or lactating women, or subjects refusing to take effective contraception measures * Other contraindications that are considered inappropriate to participate in this trial